ADVFN ADVFN

Hot Features

Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
Shenzhen Hepalink Pharmaceutical Group Company Ltd (PK)

Shenzhen Hepalink Pharmaceutical Group Company Ltd (PK) (SHEZF)

0,4696
0,00
(0,00%)
Fermé 11 Juillet 10:00PM

Shenzhen Hepalink Pharmaceutical Group Company Ltd (PK) (SHEZF) Action

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Statistiques et détails clés

Dernier
0,4696
( - )
Prix Achat
0,4989
Prix Vente
0,5789
Volume échangé
-
Volume moyen (3 m)
US$ 4 736 031
Volume financier
-
0,00 Fourchette du Jour 0,00
0,4696 Plage de 52 semaines 0,4696
Cap du marché
Valeur d'Entreprise
12,296B
Clôture Veille
0,4696
Ouverture
-
Dernière Transaction
Dernière heure de transaction
VWAP
-
Chiffre d'affairess (LTM)
5,42B
Bénéfice net (LTM)
380,47M
Actions en circulation
1 467 296 204
Flottant (%)
28,14%
Détention Institutionnelle (%)
3,42%
Rendement du Dividende (LTM)
0,15 (1,51%)
Ratio Cours sur Bénéfices
36,13
Ratio Cours/Ventes (P/S)
2,31
Bénéfice par action (BPA)
0,26
Bêta
0,31

À propos de Shenzhen Hepalink Pharmaceutical Group Company Ltd (PK)

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. provides pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. It operates in four segments: Pharmaceutical preparations, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing O... Shenzhen Hepalink Pharmaceutical Group Co., Ltd. provides pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. It operates in four segments: Pharmaceutical preparations, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization (CDMO), and Others. The company offers pharmaceutical preparations products, such as enoxaparin sodium injection; API products, including heparin and enoxaparin sodium APIs. It also provides molecule biologics CDMO services, which include research and development, manufacturing, quality management, and program management services, as well as technical support services. In addition, the company develops apabetalone (RVX-208), a BET bromodomain protein inhibitor in Phase 3 trial to reduce major adverse cardiovascular events, as well as in Phase 2 trial for diabetic nephropathy and fatty disease; oregovomab, a monoclonal antibody in Phase 3 trial for ovarian cancer, as well as in Phase 2 for pancreatic cancer; tosatoxumab (AR-301), a fully human IgG1 monoclonal antibody in Phase 3 trial for ventilator-associated pneumonia; and H1710, a heparanase inhibitor preparation for solid tumors. Further, it engages in property management, investment management and consulting, biopharmaceutical technology development and consulting, and equity and venture investment activities; provision of services on pharmaceutical related activities; and trading of medical and biopharmaceutical products. Shenzhen Hepalink Pharmaceutical Group Co., Ltd. was formerly known as Shenzhen Hepalink Pharmaceutical Co.,Ltd. and changed its name to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017. The company was founded in 1998 and is headquartered in Shenzhen, the People’s Republic of China. Show more

Secteur
-
Industrie
-
Site Web
Siège social
Shenzhen, China
Fondé
1998
Shenzhen Hepalink Pharmaceutical Group Company Ltd (PK) est coté dans le secteur de la OTC Markets avec le ticker SHEZF. Le dernier cours de clôture d'Shenzhen Hepalink Pharma... (PK) était de US$0,47. Au cours de la dernière année, les actions de Shenzhen Hepalink Pharma... (PK) ont été négociées dans une fourchette de prix de US$ 0,4696 à US$ 0,4696.

Shenzhen Hepalink Pharma... (PK) compte actuellement 1 467 296 204 actions en circulation. La capitalisation boursière d'Shenzhen Hepalink Pharma... (PK) est de US$689,04 million. Shenzhen Hepalink Pharma... (PK) a un ratio cours/bénéfice (ratio PE) de 36.13.

SHEZF Dernières nouvelles

Aucune actualité à afficher pour le moment.
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10000000CS
40000000CS
12000.46960.46960.469600CS
26000.46960.46960.469600CS
52000.46960.46960.469600CS
156-0.251-34.83208437410.72060.72060.4696130.4696CS
260-0.6956-59.69790593891.16521.50.46963461.09111582CS

SHEZF - Frequently Asked Questions (FAQ)

What is the current Shenzhen Hepalink Pharmaceutical Group Company Ltd (PK) share price?
The current share price of Shenzhen Hepalink Pharmaceutical Group Company Ltd (PK) is US$ 0,4696
How many Shenzhen Hepalink Pharmaceutical Group Company Ltd (PK) shares are in issue?
Shenzhen Hepalink Pharmaceutical Group Company Ltd (PK) has 1 467 296 204 shares in issue
What is the market cap of Shenzhen Hepalink Pharmaceutical Group Company Ltd (PK)?
The market capitalisation of Shenzhen Hepalink Pharmaceutical Group Company Ltd (PK) is USD 689,04M
What is the 1 year trading range for Shenzhen Hepalink Pharmaceutical Group Company Ltd (PK) share price?
Shenzhen Hepalink Pharmaceutical Group Company Ltd (PK) has traded in the range of US$ 0,4696 to US$ 0,4696 during the past year
What is the PE ratio of Shenzhen Hepalink Pharmaceutical Group Company Ltd (PK)?
The price to earnings ratio of Shenzhen Hepalink Pharmaceutical Group Company Ltd (PK) is 36,13
What is the cash to sales ratio of Shenzhen Hepalink Pharmaceutical Group Company Ltd (PK)?
The cash to sales ratio of Shenzhen Hepalink Pharmaceutical Group Company Ltd (PK) is 2,31
What is the registered address of Shenzhen Hepalink Pharmaceutical Group Company Ltd (PK)?
The registered address for Shenzhen Hepalink Pharmaceutical Group Company Ltd (PK) is No. 21 Langshan Road, Shenzhen, Guangdong Province, 518057
What is the Shenzhen Hepalink Pharmaceutical Group Company Ltd (PK) website address?
The website address for Shenzhen Hepalink Pharmaceutical Group Company Ltd (PK) is www.hepalink.com

SHEZF Transactions

Plus

Transactions différées

Pour obtenir des transactions en temps réel, améliorez votre compte

Passer à la version en temps réel
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

Delayed Upgrade Clock